Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
LPA gene
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "LPA gene" in MCE Product Catalog:
Cat. No.: HY-153492A
Purity: 98.82%
Synonyms: AMG 890 sodium; ARC-LPA sodium
Target:
Research Areas:
Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis .
Cat. No.: HY-177640
CAS No.: 2808361-18-2
Synonyms: LY3819469
Research Areas:
Lepodisiran (LY3819469) is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran can be used in studies related to atherosclerotic cardiovascular disease .
Cat. No.: HY-177640A
CAS No.: 2766131-24-0
Synonyms: LY3819469 sodium
Research Areas:
Lepodisiran (LY3819469) sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
Cat. No.: HY-RS07745
Target:
Research Areas:
LPA Human Pre-designed siRNA Set A contains three designed siRNAs for LPA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-130011
CAS No.: 2349373-70-0
Research Areas:
CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression .
Cat. No.: HY-177640C
Research Areas:
FAM labled Lepodisiran (LY3819469) sodiumis a FAM labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
Cat. No.: HY-177640D
Research Areas:
Cy3 labled Lepodisiran (LY3819469) sodium is a Cy3 labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
